

FULL ESTIMATED COST ENTRY SESSION
561.62 561.83

FILE 'CAPLUS' ENTERED AT 09:08:01 ON 22 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Aug 2006 VOL 145 ISS 9
FILE LAST UPDATED: 21 Aug 2006 (20060821/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 120

L21 4 L20

=> d bib abs hitstr 1-4

L21 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1042214 CAPLUS

DN 143:326204

TI Benzylactam derivatives as modulators of serotonin 1 receptors, their preparation, pharmaceutical compositions, and use in therapy

IN Brodney, Michael Aaron; Caron, Stephane; Helal, Christopher J.; Raggon, Jeffrey W.; Tao, Yong; Do, Nga M.

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005090300	A1	20050929	WO 2005-IB583	20050307
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	NL 1028558	A1	20050920	NL 2005-1028558	20050316
	US 2005245521	A1	20051103	US 2005-83188	20050317
PRAI	US 2004-553808P	P	20040317		
OS	MARPAT 143:326204				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to benzyl(idene)-lactam derivs. I, which are modulators of serotonin 1 (5-HT₁) receptors. In compds. I, n is 1-3; R₁ is substituted piperazin-1-yl or piperidin-4-yl; X is H, Cl, F, Br, I, cyano, C1-6 alkyl, OH, C1-6 alkoxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, carboxy, or aminocarbonyl; R₃ is -(CH₂)_g-B, where g is 0-3 and B is H, (un)substituted Ph, (un)substituted naphthyl, or a 5- or 6-membered (un)substituted heteroaryl ring containing one to four heteroatoms, selected from O, N, and S; or corresponding benzylidene derivs., pharmaceutically acceptable salts or optical isomers thereof. The invention also relates to the preparation of I, pharmaceutical compns.

containing I

with a pharmaceutically acceptable carrier, as well as to the use of the compds. for treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT₁ agonist or antagonist is indicated. Regioselective substitution of 2,5-difluorobenzaldehyde with 1-methylpiperazine followed by condensation with N-acetylpyrrolidin-2-one, hydrolysis, and hydrogenation resulted in the formation of pyrrolidinone II. Compound II was coupled to 2-(4-bromophenyl)-propan-2-ol, prepared by addition of methylmagnesium bromide to Me 4-bromobenzoate, to give benzylactam III. All tested compds. had IC₅₀ values of 1000 nM or less. The compds. of the invention include selective antagonists, inverse agonists and partial agonists of 5-HT₁ receptors (no specific data).


IT 865204-44-0P, 3-[2-(4-Methylpiperazin-1-yl)benzyl]-1-[4-(2-oxopyrrolidin-1-ylmethyl)phenyl]piperidin-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzylactam derivs. as modulators of serotonin 1 receptors)

RN 865204-44-0 CAPLUS

CN 2-Piperidinone, 3-[[2-(4-methyl-1-piperazinyl)phenyl]methyl]-1-[4-[(2-oxo-1-pyrrolidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:772650 CAPLUS

DN 141:295862
 TI A preparation of cyclohexyl and piperidinyl derivatives, useful as
 melanocortin-4 receptor modulators
 IN Soeberdt, Michael; Weyermann, Philipp; Von Sprecher, Andreas
 PA Myocontract Ltd., Switz.
 SO Eur. Pat. Appl., 95 pp.
 CODEN: EPXXDW

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1460069	A1	20040922	EP 2003-6255	20030320
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	AU 2004222097	A1	20040930	AU 2004-222097	20040319
	CA 2519372	AA	20040930	CA 2004-2519372	20040319
	WO 2004083198	A1	20040930	WO 2004-EP2909	20040319
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1606278	A1	20051221	EP 2004-721881	20040319
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
PRAI	EP 2003-6255	A	20030320		
	WO 2004-EP2909	A	20040319		
OS	MARPAT 141:295862				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to novel substituted cyclohexyl and piperidinyl derivs. of formula I [wherein: X is N or CH; Y is (CH₂)₀₋₂; Z is (CH₂)₀₋₂; R₁ is H, OH, CN, NO₂, alkyl, alkoxy, or -D-C(O)-heteroaryl, etc; R₂ is derivative of pyridine, piperidine, or isoindole, etc.; R₃ is -D-(hetero)aryl; R₄ is H or bond; D is a bond or alkylene], useful as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Representative compds. of the invention were tested in functional assay and found to activate the melanocortin-4-receptor with EC₅₀ values less than 1 µM. For instance, cyclohexane derivative II•HCl (R₅ = H) was prepared via amidation of isoquinolinecarboxylic acid derivative III by the obtained amine IV•HCl and subsequent N-cleavage of the obtained amide II (R₅ = BOC) (example 1, no yield data).


IT 760972-65-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclohexyl and piperidinyl derivs., useful as melanocortin-4 receptor modulators)


RN 760972-65-4 CAPLUS
 CN 3-Isoquinolinecarboxamide, N-[(1S)-1-[(4-chlorophenyl)methyl]-2-[1-[2-[(2-oxo-1-pyrrolidinyl)methyl]phenyl]-4-piperidinylidene]ethyl]-1,2,3,4-tetrahydro-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 760972-73-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of cyclohexyl and piperidinyl derivs., useful as melanocortin-4 receptor modulators)
 RN 760972-73-4 CAPLUS
 CN 2(1H)-Isoquinolinecarboxylic acid, 3-[[[(1S)-1-[(4-chlorophenyl)methyl]-2-[1-[2-[(2-oxo-1-pyrrolidinyl)methyl]phenyl]-4-piperidinylidene]ethyl]amino]carbonyl]-3,4-dihydro-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



L21 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:372868 CAPLUS
 DN 140:375080
 TI Preparation of phenylpiperidines and phenylpyrrolidines as histamine H3 receptor inhibitors

IN Apodaca, Richard L.; Dvorak, Curt A.; Shah, Chandravadan R.; Xiao, Wei
 PA USA
 SO U.S. Pat. Appl. Publ., 47 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004087573	A1	20040506	US 2003-692080	20031023
PRAI	US 2002-420494P	P	20021023		
OS	MARPAT 140:375080				
GI					



AB Substituted phenylpiperidines and phenylpyrrolidines of formula I [L = bond, alkylene, etc.; R1,R2 = H, alkyl, cycloalkyl, heterocyclyl, etc.; R1R2 = alkylene, heteroalkylene, etc.; R3-R5 = H, halo, nitro, CF3, Me, alkoxy; R6 = alkyl, CF3; X = (CH2)p; Y = (CH2)q; p = 0-2; q = 1-2; m = 0-3], comps. containing them, and methods of making and using them to treat histamine-mediated conditions are described. Thus, II was prepared from 1-(4-pyrrolidinomethylphenyl)piperidin-4-carbaldehyde and cyclohexylamine. The Ki value of II was 0.9 nM in {3H}-N-methylhistamine binding assay.


IT 683772-25-0P 683772-28-3P 683772-29-4P
 683772-30-7P 683772-31-8P 683772-32-9P
 683772-33-0P 683772-34-1P 683772-35-2P
 683772-36-3P 683772-37-4P 683772-39-6P
 683772-40-9P 683772-41-0P 683772-42-1P
 683772-44-3P 683772-46-5P 683772-52-3P
 683772-57-8P 683772-59-0P 683772-69-2P
 683772-70-5P 683772-71-6P 683772-72-7P
 683772-73-8P 683772-74-9P 683772-75-0P
 683772-76-1P 683772-77-2P 683772-78-3P
 683772-79-4P 683772-81-8P 683772-82-9P
 683772-83-0P 683775-76-0P

RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylpiperidines and phenylpyrrolidines as histamine H3 receptor inhibitors)


RN 683772-25-0 CAPLUS

CN Azacyclotridecane, 1-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-28-3 CAPLUS
 CN Piperazine, 1-methyl-4-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 683772-29-4 CAPLUS
 CN 4-Piperidinol, 1-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-30-7 CAPLUS
 CN Thiomorpholine, 4-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-31-8 CAPLUS
 CN Piperidine, 4-(1-piperidinylmethyl)-1-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 683772-32-9 CAPLUS
 CN Morpholine, 4-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-33-0 CAPLUS

CN Thiomorpholine, 4-[[3-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-34-1 CAPLUS

CN Morpholine, 4-[[3-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-35-2 CAPLUS

CN Piperidine, 4-[(1-pyrrolidin-1-yl)methyl]-1-[3-[(1-pyrrolidin-1-yl)methyl]phenyl]-
(9CI) (CA INDEX NAME)




RN 683772-36-3 CAPLUS

CN Piperidine, 1-[3-[(1-piperidin-1-yl)methyl]phenyl]-4-[(1-pyrrolidin-1-yl)methyl]-
(9CI) (CA INDEX NAME)




RN 683772-37-4 CAPLUS

CN Azacyclotridecane, 1-[[4-[[4-[(1-pyrrolidin-1-yl)methyl]-1-piperidin-1-yl]phenyl]methyl]-
(9CI) (CA INDEX NAME)




RN 683772-39-6 CAPLUS
 CN 4-Piperidinol, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 683772-40-9 CAPLUS
CN Piperazine, 1-methyl-4-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 683772-41-0 CAPLUS
CN Thiomorpholine, 4-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-42-1 CAPLUS
 CN Morpholine, 4-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]-
 (9CI) (CA INDEX NAME)




RN 683772-44-3 CAPLUS
 CN Morpholine, 4-[[2-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]-
 (9CI) (CA INDEX NAME)




RN 683772-46-5 CAPLUS

CN Piperidine, 1-[4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)-
(9CI) (CA INDEX NAME)




RN 683772-52-3 CAPLUS

CN Morpholine, 4-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]methyl]- (9CI)
(CA INDEX NAME)




RN 683772-57-8 CAPLUS

CN 2-Pyridinamine, N-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-59-0 CAPLUS

CN Piperidine, 4-(1-pyrrolidinylmethyl)-1-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 683772-69-2 CAPLUS

CN Piperidine, 1-[4-(1-piperidinylmethyl)-2-(trifluoromethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-70-5 CAPLUS

CN Piperidine, 1-[2-nitro-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-71-6 CAPLUS

CN Morpholine, 4-[[3-nitro-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-72-7 CAPLUS
 CN 4-Piperidinol, 1-[[3-nitro-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 683772-73-8 CAPLUS
 CN Piperidine, 1-[4-(1-piperidinylmethyl)-3-(trifluoromethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-74-9 CAPLUS
 CN Piperazine, 1-(1-methylethyl)-4-[[3-methyl-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




PAGE 1-A




RN 683772-75-0 CAPLUS
 CN Piperidine, 1-[2-methyl-4-(1-pyrrolidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-76-1 CAPLUS
 CN Piperidine, 1-[2-methyl-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-77-2 CAPLUS
 CN Piperidine, 4-(1-pyrrolidinylmethyl)-1-[4-[[4-(1-pyrrolidinyl)-1-piperidinyl]methyl]-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 683772-78-3 CAPLUS
 CN Piperidine, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-2-

(trifluoromethyl)phenyl]methyl]-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA
INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 683772-79-4 CAPLUS


CN Piperidine, 1-[2-fluoro-4-[(4-phenyl-1-piperidinyl)methyl]phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-81-8 CAPLUS
 CN Piperidine, 1-[2-fluoro-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-82-9 CAPLUS
 CN 1,4,7,10-Tetraoxa-13-azacyclopentadecane, 13-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-83-0 CAPLUS
 CN 4-Piperidinemethanol, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 683775-76-0 CAPLUS
 CN Methanesulfonic acid, trifluoro-, compd. with 13-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-2-(trifluoromethyl)phenyl]methyl]-1,4,7,10-tetraoxa-13-azacyclopentadecane (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 683772-82-9
 CMF C28 H44 F3 N3 O4



CM 2



CRN 1493-13-6

CMF C H F3 O3 S



L21 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:368927 CAPLUS
 DN 140:391199
 TI Preparation of phenylpiperidines and phenylpyrrolidines as histamine H3
 receptor modulators
 IN Apodaca, Richard L.; Dvorak, Curt A.; Shah, Chandravadan R.; Xiao, Wei
 PA Janssen Pharmaceutica, N.V., Belg.
 SO PCT Int. Appl., 115 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037257	A1	20040506	WO 2003-US33809	20031023
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2504272	AA	20040506	CA 2003-2504272	20031023
AU 2003287206	A1	20040513	AU 2003-287206	20031023
EP 1556046	A1	20050727	EP 2003-781386	20031023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006505590	T2	20060216	JP 2004-547134	20031023
PRAI US 2002-420494P	P	20021023		
WO 2003-US33809	W	20031023		
OS MARPAT 140:391199				
GI				



AB The title compds. [I; L = a bond, alkylene, alkenylene, etc.; p = 0-2; q = 1-2 (provided that 2≤p+q≤4); R1, R2 = H, alkyl, Ph, etc.; or NR1R2 = (un)substituted saturated 3-13 membered heterocyclyl; one R3-R5 = G and the other two = H, F, Cl, Br, NO2, CF3, Me, alkoxy; G = L2Q; L2 = (CH2)n; n = 1-7; Q = NR8R9 (R8, R9 = H, alkyl, Ph, etc.; or NR8R9 = (un)substituted saturated 3-15 membered heterocyclyl); R6 = H, alkyl; CF3; m = 0-3], useful for treating histamine-mediated conditions, were prepared Thus, 1-[2-(morpholin-4-ylmethyl)phenyl]piperidine-4-carbaldehyde with piperidine in the presence of NaBH(OAc)3 in DCE afforded II which showed Ki of 4500 nM against H3 receptor binding. The pharmaceutical compns. comprising the compds. I are claimed.


IT 683772-25-0P 683772-28-3P 683772-29-4P
683772-30-7P 683772-31-8P 683772-32-9P
683772-33-0P 683772-34-1P 683772-35-2P
683772-36-3P 683772-37-4P 683772-39-6P
683772-40-9P 683772-41-0P 683772-42-1P
683772-44-3P 683772-46-5P 683772-52-3P
683772-57-8P 683772-59-0P 683772-69-2P
683772-70-5P 683772-71-6P 683772-72-7P
683772-73-8P 683772-74-9P 683772-75-0P
683772-76-1P 683772-77-2P 683772-78-3P
683772-79-4P 683772-81-8P 683772-83-0P
683775-76-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylpiperidines and phenylpyrrolidines as histamine H3 receptor modulators)

RN 683772-25-0 CAPLUS


CN Azacyclotridecane, 1-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-28-3 CAPLUS

CN Piperazine, 1-methyl-4-[[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 683772-29-4 CAPLUS
 CN 4-Piperidinol, 1-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-30-7 CAPLUS
 CN Thiomorpholine, 4-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-31-8 CAPLUS
 CN Piperidine, 4-(1-piperidinylmethyl)-1-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 683772-32-9 CAPLUS
 CN Morpholine, 4-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-33-0 CAPLUS

CN Thiomorpholine, 4-[[3-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-34-1 CAPLUS

CN Morpholine, 4-[[3-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-35-2 CAPLUS

CN Piperidine, 4-(1-pyrrolidinylmethyl)-1-[3-(1-pyrrolidinylmethyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 683772-36-3 CAPLUS

CN Piperidine, 1-[3-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)-
(9CI) (CA INDEX NAME)



RN 683772-37-4 CAPLUS


CN Azacyclotridecane, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-39-6 CAPLUS

CN 4-Piperidinol, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 683772-40-9 CAPLUS
CN Piperazine, 1-methyl-4-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 683772-41-0 CAPLUS
CN Thiomorpholine, 4-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-42-1 CAPLUS
 CN Morpholine, 4-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]-
 (9CI) (CA INDEX NAME)




RN 683772-44-3 CAPLUS
 CN Morpholine, 4-[[2-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]-
 (9CI) (CA INDEX NAME)




RN 683772-46-5 CAPLUS

CN Piperidine, 1-[4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)-
(9CI) (CA INDEX NAME)




RN 683772-52-3 CAPLUS

CN Morpholine, 4-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]methyl]- (9CI)
(CA INDEX NAME)




RN 683772-57-8 CAPLUS

CN 2-Pyridinamine, N-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-59-0 CAPLUS

CN Piperidine, 4-(1-pyrrolidinylmethyl)-1-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 683772-69-2 CAPLUS

CN Piperidine, 1-[4-(1-piperidinylmethyl)-2-(trifluoromethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-70-5 CAPLUS

CN Piperidine, 1-[2-nitro-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-71-6 CAPLUS

CN Morpholine, 4-[[[3-nitro-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 683772-72-7 CAPLUS
 CN 4-Piperidinol, 1-[[3-nitro-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 683772-73-8 CAPLUS
 CN Piperidine, 1-[4-(1-piperidinylmethyl)-3-(trifluoromethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-74-9 CAPLUS
 CN Piperazine, 1-(1-methylethyl)-4-[[3-methyl-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




PAGE 1-A




RN 683772-75-0 CAPLUS

CN Piperidine, 1-[2-methyl-4-(1-pyrrolidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-76-1 CAPLUS

CN Piperidine, 1-[2-methyl-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-77-2 CAPLUS

CN Piperidine, 4-(1-pyrrolidinylmethyl)-1-[4-[[4-(1-pyrrolidinyl)-1-piperidinyl]methyl]-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 683772-78-3 CAPLUS


CN Piperidine, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-2-

(trifluoromethyl)phenyl)methyl]-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA
INDEX NAME)



PAGE 1-A




PAGE 2-A



RN 683772-79-4 CAPLUS
CN Piperidine, 1-[2-fluoro-4-[(4-phenyl-1-piperidinyl)methyl]phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-81-8 CAPLUS
 CN Piperidine, 1-[2-fluoro-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 683772-83-0 CAPLUS
 CN 4-Piperidinemethanol, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 683775-76-0 CAPLUS
 CN Methanesulfonic acid, trifluoro-, compd. with 13-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-2-(trifluoromethyl)phenyl]methyl]-1,4,7,10-tetraoxa-13-azacyclopentadecane (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 683772-82-9
 CMF C28 H44 F3 N3 O4



CM 2

CRN 1493-13-6
CMF C H F3 O3 S




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 11

L1	STR
----	-----



=> d 17
 L7 HAS NO ANSWERS
 L7 STR



REP G1=(0-5) C
 VAR G2=8/9/10
 VAR G3=2/1/19/20/5
 NODE ATTRIBUTES:
 NSPEC IS R AT 18
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 6 3
 NUMBER OF NODES IS 21


STEREO ATTRIBUTES: NONE

=> s 17 ful
 FULL SEARCH INITIATED 11:37:51 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 834435 TO ITERATE

100.0% PROCESSED 834435 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.10

L9 0 SEA SSS FUL L7

=> d 112
 L12 HAS NO ANSWERS
 L12 STR



VAR G2=8/9/10
 NODE ATTRIBUTES:
 NSPEC IS R AT 18
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 6 3
 NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

=> s 112 ful
 FULL SEARCH INITIATED 09:01:29 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 825173 TO ITERATE

100.0% PROCESSED 825173 ITERATIONS
 SEARCH TIME: 00.00.10


518 ANSWERS

L14 518 SEA SSS FUL L12

=> s 114 and piperidin?
 976018 PIPERIDIN?
 L15 472 L14 AND PIPERIDIN?

=> d scan


L15 472 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Piperazine, 1-[4-(4-methyl-1-piperidinyl)-3-nitrobenzoyl]-4-(phenylsulfonyl)- (9CI)
 MF C23 H28 N4 O5 S



=> d l16

L16 HAS NO ANSWERS

L16 STR



REP G1=(1-8) CH

VAR G2=8/9/10

NODE ATTRIBUTES:

NSPEC IS R AT 18

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 6 3

NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

=> search l16

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss

ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset

ENTER SUBSET L# OR (END):l15

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful

FULL SUBSET SEARCH INITIATED 09:03:00 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 472 TO ITERATE

100.0% PROCESSED 472 ITERATIONS


114 ANSWERS

SEARCH TIME: 00.00.01

L17 114 SEA SUB=L15 SSS FUL L16

=> s l17 and pyrrolidin?
 582391 PYRROLIDIN?
 L20 39 L17 AND PYRROLIDIN?
 => d scan


L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Piperidine, 1-[2-nitro-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI)
 MF C22 H34 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10


L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 4-Piperidinol, 1-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI)
 MF C22 H35 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Morpholine, 4-[[3-nitro-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI)
 MF C21 H32 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Thiomorpholine, 4-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI)
 MF C21 H33 N3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4-Piperidinol, 1-[[3-nitro-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI)
MF C22 H34 N4 O3

PAGE 1-A




PAGE 2-A




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Piperidine, 4-(1-piperidinylmethyl)-1-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI)
MF C22 H35 N3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Piperidine, 1-[4-(1-piperidinylmethyl)-3-(trifluoromethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI)
MF C23 H34 F3 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Morpholine, 4-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI)
MF C21 H33 N3 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Piperazine, 1-(1-methylethyl)-4-[[3-methyl-4-[[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI)
 MF C25 H42 N4


PAGE 1-A






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Thiomorpholine, 4-[[3-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI)
 MF C21 H33 N3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Piperidine, 1-[2-methyl-4-(1-pyrrolidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI)
 MF C22 H35 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL